AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 72 min read$BLLN

Atay Oguzhan sold $2.3M of BLLN

Atay Oguzhan (Chairman and CEO) sold 15,539 shares of BillionToOne, Inc. (BLLN) at $150.03 ($2.33M total) on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Aug 7, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount, date, and that it was executed under a pre-arranged Rule 10b5-1 plan; no other company-specific catalyst is provided.

02

Market read

Traders may note insider selling, but the 10b5-1 framing reduces the likelihood of a fundamental signal.

03

What to watch

The article provides only the sale details; it does not include any concurrent buy transactions, lockups, or changes in company fundamentals that would better explain trading impact.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-07, transaction dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne Form 4 shows CEO/Chairman Atay Oguzhan sold 15,539 shares on 2026-08-05 under a 10b5-1 plan for about $2.33M.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly stated 10b5-1 pre-arranged plan and no accompanying company guidance, deal, or regulatory event in the text.

Market effects

Sector

No sector-level implications disclosed; this is company-specific insider trading reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan and the CEO still holds no shares after the sale, the market may overreact to a non-informational transaction.

Key entities

  • issuer
    BillionToOne, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Atay Oguzhan

    Chairman and CEO who sold 15,539 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLLN insider trading history →

Related articles

OCT 7
$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

rttnews.com2 min
OCT 7
$BLLNMedAI 8/10

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.

globenewswire.com2 min
AUG 6
$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

benzinga.com3 min
AUG 5
$BLLNMed

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

SEC EDGAR 8-K7 min
MAY 27
$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.

dailypolitical.com1 min